Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Damora Therapeutics, Inc.GLTO · Entity 4602 | Director | June 18, 2025 | June 20, 2025 |
| Kaleido Biosciences, Inc.KLDO · Entity 129745 | Director | June 30, 2021 | July 01, 2021 |
| Keros Therapeutics, Inc.KROS · Entity 6242 | Director | July 01, 2026 | July 06, 2026 |
| Rubius Therapeutics, Inc.RUBY · Entity 116417 | Director | May 12, 2022 | May 13, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Damora Therapeutics, Inc.
Report date June 18, 2025 · Filed June 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2035-06-18 | Direct | 720 |
Reported balance
After 2025-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-18 · Grant · Acquired 720 · Balance 720 F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.
Kaleido Biosciences, Inc.
Report date June 30, 2021 · Filed July 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.44 · Expires 2031-06-29 | Direct | 15,000 |
Reported balance
After 2021-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-30 · Grant · Acquired 15,000 · Balance 15,000 |
Keros Therapeutics, Inc.
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,786 |
Reported balance
After 2026-07-01 transaction · row 1
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 13,786 · Balance 13,786 F1: Represents a restricted stock unit ("RSU") award. The RSUs shall vest over a three-year period in twelve equal quarterly installments with the first such vesting to occur on August 15, 2026, subject to the Reporting Person's continuous service through each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.88 · Expires 2036-06-30 | Direct | 14,870 |
Reported balance
After 2026-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-01 · Grant · Acquired 14,870 · Balance 14,870 F2: The shares subject to the option shall vest over a three-year period in equal quarterly installments with the first such vesting to occur on October 1, 2026, subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. The RSUs shall vest over a three-year period in twelve equal quarterly installments with the first such vesting to occur on August 15, 2026, subject to the Reporting Person's continuous service through each such vesting date.
F2: The shares subject to the option shall vest over a three-year period in equal quarterly installments with the first such vesting to occur on October 1, 2026, subject to the Reporting Person's continuous service through each such vesting date.
Rubius Therapeutics, Inc.
Report date May 12, 2022 · Filed May 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2032-05-11 | Direct | 25,000 |
Reported balance
After 2022-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-12 · Grant · Acquired 25,000 · Balance 25,000 F1: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 6, 2026 20:31 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantStock Option (right to buy) · Derivative | 14,870 | $0.00 Strike: $10.88 | $0.00 |
DisclosureSEC source: 0001797917-26-000007 · form4-07062026_080756.xml · derivative · entry 2 Prener Anne · CIK 0001797917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,870 Underlying: Common Stock · 14,870 shares Expires 2036-06-30 F2 · derivative.exercise_date: The shares subject to the option shall vest over a three-year period in equal quarterly installments with the first such vesting to occur on October 1, 2026, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 20:31 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantCommon Stock | 13,786 | $0.00 | $0.00 |
DisclosureSEC source: 0001797917-26-000007 · form4-07062026_080756.xml · nonDerivative · entry 1 Prener Anne · CIK 0001797917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,786 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest over a three-year period in twelve equal quarterly installments with the first such vesting to occur on August 15, 2026, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 11:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 720 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0000950170-25-088164 · ownership.xml · derivative · entry 1 Prener Anne · CIK 0001797917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 720 Underlying: Common Stock · 720 shares Expires 2035-06-18 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0000950170-24-076191 · ownership.xml · derivative · entry 1 Prener Anne · CIK 0001797917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 20, 2024, the date of the Issuer's 2024 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-23-037287 · doc4.xml · derivative · entry 1 Prener Anne · CIK 0001797917 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2033-06-13 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2023, the date of the Issuer's 2023 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| June 14, 2022 Filed Jun 15, 2022 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001209191-22-036934 · doc4.xml · derivative · entry 1 Prener Anne · CIK 0001797917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-06-13 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2022, the date of the Issuer's 2022 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| May 12, 2022 Filed May 13, 2022 16:35 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001179110-22-003012 · edgar.xml · derivative · entry 1 Prener Anne · CIK 0001797917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-05-11 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 16:28 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $7.44 | $0.00 |
DisclosureSEC source: 0001209191-21-044407 · doc4.xml · derivative · entry 1 Prener Anne · CIK 0001797917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-29 Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $4.93 | $0.00 |
DisclosureSEC source: 0001209191-21-036510 · doc4.xml · derivative · entry 1 Prener Anne · CIK 0001797917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2031-05-25 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on May 26, 2021, the date of the Issuer's 2021 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:34 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $23.25 | $0.00 |
DisclosureSEC source: 0001179110-21-005311 · edgar.xml · derivative · entry 1 Prener Anne · CIK 0001797917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-05-11 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. Read SEC document |
| January 08, 2021 Filed Jan 8, 2021 21:01 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $13.12 | $0.00 |
DisclosureSEC source: 0001209191-21-002693 · doc4.xml · derivative · entry 2 Prener Anne · CIK 0001797917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2031-01-08 F2 · derivative.exercise_date: Represents a pro-rated annual option grant to a non-employee director upon appointment to the Board of Directors of the Company. The shares subject to such option vest in twelve equal monthly installments, commencing on January 8, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 08, 2021 Filed Jan 8, 2021 21:01 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $13.12 | $0.00 |
DisclosureSEC source: 0001209191-21-002693 · doc4.xml · derivative · entry 1 Prener Anne · CIK 0001797917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2031-01-08 F1 · derivative.exercise_date: The shares subject to such option vest in 36 equal monthly installments over three years from the date of vesting commencement of January 8, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 16:16 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $7.43 | $0.00 |
DisclosureSEC source: 0001209191-20-039726 · doc4.xml · derivative · entry 1 Prener Anne · CIK 0001797917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-29 Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 08:57 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $5.21 | $0.00 |
DisclosureSEC source: 0000899243-20-010048 · doc4.xml · derivative · entry 1 Prener Anne · CIK 0001797917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-04-01 F1 · derivative.exercise_date: Thirty three percent of this option shall vest on April 1, 2021, with the remainder vesting in two equal annual installments thereafter, subject to Dr. Prener's continued service on the board of directors through each such date. This grant was made in accordance with the Company's Non-Employee Director Compensation Policy. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 14:55 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0001104659-20-000769 · a4.xml · derivative · entry 1 Prener Anne · CIK 0001797917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-12-30 F1 · derivative.exercise_date: This option shall vest in equal quarterly installments over the twelve quarters following the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.